Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1822353 | 0.98 | ENPP2 (0.50) | ENPP2KDM4EALDH1A1TTRALB | |
| SCHEMBL27908 | 0.84 | ENPP2 (0.61) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL15602898 | 0.84 | ENPP2 (0.61) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL29952148 | 0.77 | ENPP2 (0.53) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL3182180 | 0.77 | TTR (0.40) | KDM4EALDH1A1TTRALBMEN1 | |
| SCHEMBL190209 | 0.77 | ENPP2 (0.56) | ENPP2KDM4EALDH1A1 | |
| SCHEMBL2011602 | 0.77 | TTR (0.40) | KDM4EALDH1A1TTRALBMEN1 | |
| SCHEMBL29954891 | 0.76 | ENPP2 (0.48) | ENPP2TTRALBMEN1KMT2A | |
| SCHEMBL874242 | 0.75 | ENPP2 (0.52) | ENPP2 | |
| SCHEMBL16398417 | 0.75 | ENPP2 (0.52) | ENPP2ALDH1A1TTRALBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4705292-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250362134-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2025108234-A1 | COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦药物研究院有限公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025076299-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119504808-A | Compound, preparation method and application thereof | 四川科伦药物研究院有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240425497-A1 | Cbl-b Inhibitors and Methods of Use Thereof | ARCUS BIOSCIENCES, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| CN-116077655-B | Boron-containing medicine and its preparation method | 成都纽瑞特医疗科技股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024233360-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2015053975-A1 | VOLUME RESPONSE SENSORS HAVING CONTROLLED REVERSIBLE CROSSLINKING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-16 | — | — | WO | disclosed |
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | ENPP2 642/4885KDM4E 3004/4885ALDH1A1 2484/4885 |
| US-20240425497-A1 | Cbl-b Inhibitors and Methods of Use Thereof | CBLB, CBL, CBLC | ENPP2 1489/4885KDM4E 1482/4885ALDH1A1 4261/4885 |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBLC, CBL | ENPP2 2669/4885KDM4E 2320/4885ALDH1A1 3286/4885 |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | ENPP2 698/4885KDM4E 4105/4885ALDH1A1 4162/4885 |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | ENPP2 3589/4885KDM4E 928/4885ALDH1A1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.